Search

Displaying results 2981 - 2990 of 10000 in total
  1. Drug

    Selpercatinib

    go.drugbank.com/drugs/DB15685
    ApprovedInvestigational

    [A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific … Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated

  2. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. … It was rejected for approval for use in the United States.

  3. Drug

    Prostaglandin D2

    go.drugbank.com/drugs/DB02056
    Experimental

    The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, ...

    Synonyms: Prostaglandin D2Categories: Prostaglandins D, Prostaglandin D2, antagonists & inhibitors
  4. Drug

    Methyl-D9-choline

    go.drugbank.com/drugs/DB12628
    Investigational

    Methyl-D9-choline is under investigation in clinical trial NCT01807910 (ER Stress in NAFLD).

  5. Drug

    Plinabulin

    go.drugbank.com/drugs/DB05992
    Investigational

  6. Drug

    Picrotoxin

    go.drugbank.com/drugs/DB00466
    Experimental

    Although it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates. [PubChem]

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Anifrolumab

    go.drugbank.com/drugs/DB11976
    ApprovedInvestigational

    [A237044] Anifrolumab was granted FDA approval on 30 July 2021.[L34929] … Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus.

  8. Drug

    CYT006-AngQb

    go.drugbank.com/drugs/DB05739
    Investigational

    It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient dosing schedules due to the long-lasting effect induced by vaccination. … CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension.

  9. Drug

    Bisphosphocin Nu-3

    go.drugbank.com/drugs/DB16015
    Investigational

    Bisphosphocin Nu-3 is under investigation in clinical trial NCT02737722 (Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus).

    Synonyms: Nu-3, Bisphosphocin Nu-3
  10. Drug

    Donanemab

    go.drugbank.com/drugs/DB16647
    ApprovedInvestigational

    [A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms. … Donanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta (Aβ), [L50978] which is found in the brain amyloid plaques that